Supracervical hysterectomy.
OBJECTIVE
This guideline reviews the evidence relating to the potential benefits of the vaginal hysterectomy (VH) and supracervical hysterectomy (SCH) versus total abdominal hysterectomy (TAH) with respect to postoperative sexual function, urinary function, and peri- and postoperative complications. Laparoscopic options are not included in this guideline.


METHODS
Women considering hysterectomy for benign disease can be given the option of retaining the cervix or proceeding with a total hysterectomy.


RESULTS
The outcomes measured are postoperative sexual function and urinary function, and peri- and postoperative complications.


METHODS
The Cochrane Library, Medline, and Embase were searched for articles published in English from January 1950 to March 2008 specifically comparing VH and SCH with TAH in the prevention of sexual dysfunction, urinary dysfunction, and peri- and postoperative complications. Results were restricted to systematic reviews, randomized control trials/controlled clinical trials, and observational studies. Additional publications were identified from the bibliographies of these articles. Randomized controlled trials were considered evidence of the highest quality, followed by cohort studies. Grey (unpublished) literature was identified through searching the websites of health technology assessment and health technology assessment-related agencies, clinical practice guideline collections, clinical trial registries, and national and international medical specialty societies.


METHODS
The quality of evidence was rated using the criteria described in the Report of the Canadian Task Force on Preventive Health Care (Table).


CONCLUSIONS
1. Vaginal hysterectomy is generally considered the first choice of surgical approach for most benign indications for hysterectomy, as it is associated with lower rates of morbidity, fewer postoperative complications, and a faster recovery time than abdominal hysterectomy. (I-A). 2. Women contemplating a vaginal, laparoscopic, or abdominal hysterectomy for the management of benign uterine disease should be reassured that hysterectomy is usually associated with improved quality of life, including improved sexual function, whether or not the cervix is removed. (I-B). 3. Supracervical hysterectomy should not be recommended as a superior technique to total abdominal hysterectomy for the prevention of postoperative lower urinary tract symptoms. (I-B). 4. Although supracervical hysterectomy may be associated with less blood loss and a shorter surgical time, these parameters have not been found to be clinically significant, and supracervical hysterectomy should not be recommended as a superior technique to total abdominal hysterectomy for the prevention of peri- and postoperative complications. (I-B). 5. Women considering a supracervical hysterectomy should be counselled that they may continue experiencing cyclic vaginal bleeding following the surgery. (I-B). 6. Women must be advised that they require routine cytological screening following a supracervical hysterectomy. (II-B). 7. Women who require a hysterectomy and who have a current or significant history of abnormal cervical cytological results should be counselled on the advantages of vaginal hysterectomy or total abdominal hysterectomy over supracervical hysterectomy. (I-B).
Kives
Sari
S
Toronto ON.
Lefebvre
Guylaine
G
Toronto ON.
D002584:Cervix Uteri; D005260:Female; D017048:Health Care Costs; D006801:Humans; D007044:Hysterectomy / Q000191:economics / Q000379:methods*; D007045:Hysterectomy, Vaginal; D007431:Intraoperative Complications / Q000517:prevention & control; D011183:Postoperative Complications / Q000517:prevention & control; D011788:Quality of Life; D016032:Randomized Controlled Trials as Topic; D012735:Sexual Dysfunction, Physiological / Q000517:prevention & control; D020018:Sexual Dysfunctions, Psychological / Q000517:prevention & control; D014570:Urologic Diseases / Q000517:prevention & control